Lee Nadell
Psychiatric/Mental Health · Long Beach, NYNPI 1508346321
Payments from drug & device makers
Across 150 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$561
- Alkermes, Inc.$442
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$316
- Lundbeck LLC$277
- Axsome Therapeutics, Inc.$202
- Sunovion Pharmaceuticals Inc.$184
- plus $1K from 12 others
What the payments were for
- Food & beverage$3,057100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $561 |
| Alkermes, Inc. | 22 | $442 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $316 |
| Lundbeck LLC | 13 | $277 |
| Axsome Therapeutics, Inc. | 8 | $202 |
| Sunovion Pharmaceuticals Inc. | 10 | $184 |
| Otsuka America Pharmaceutical, Inc. | 9 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $155 |
| Corium, LLC | 7 | $126 |
| E.r. Squibb & Sons, L.L.C. | 6 | $125 |
| Neurocrine Biosciences, Inc. | 5 | $102 |
| Johnson & Johnson | 3 | $82 |
| Ironshore Pharmaceuticals Inc. | 4 | $81 |
| Indivior Inc. | 4 | $80 |
| Braeburn Inc. | 3 | $76 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Tris Pharma Inc | 1 | $20 |
How this compares
$3,057 in reported general payments places this provider in the 85th percentile of 2,385 psychiatric/mental health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 21 | $35,208 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,469 |
| Fluvoxamine Maleate | 11 | $1,230 |
| Bupropion XlBupropion Hcl | 41 | $775 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 24 | $698 |
| Escitalopram Oxalate | 47 | $450 |
| Buspirone Hcl | 18 | $445 |
| Quetiapine Fumarate | 43 | $400 |
| Duloxetine Hcl | 21 | $251 |
| Methylphenidate ErMethylphenidate Hcl | 11 | $218 |
| Risperidone | 24 | $215 |
| Sertraline Hcl | 18 | $208 |
| Clonazepam | 35 | $81 |
| Trazodone Hcl | 16 | $80 |
| Prazosin Hcl | 12 | $80 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $561 | $35,20821 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $155 | $5,46912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Long Beach
- Glenn HannDansville$1.3M
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Mary OlsonNew York$142K
- Elijah StevensBinghamton$131K
- Kayanna JonasFar Rockaway$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.